Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

Kazda, Christof M; Ding, Ying; Kelly, Ronan P; Garhyan, Parag; Shi, Chunxue; Lim, Chay Ngee; Fu, Haoda; Watson, David E; Lewin, Andrew J; Landschulz, William H; Deeg, Mark A; Moller, David E; Hardy, Thomas A

Kazda, Christof M; Ding, Ying; Kelly, Ronan P; Garhyan, Parag; Shi, Chunxue; Lim, Chay Ngee; Fu, Haoda; Watson, David E; Lewin, Andrew J; Landschulz, William H; Deeg, Mark A; Moller, David E; Hardy, Thomas A.

Afiliação

Kazda CM; Eli Lilly and Company, Suresnes, France kazda_christof@lilly.com.
Ding Y; Eli Lilly and Company, Indianapolis, IN.
Kelly RP; Lilly-NUS Centre for Clinical Pharmacology, Singapore.
Garhyan P; Eli Lilly and Company, Indianapolis, IN.
Shi C; inVentiv Health Clinical, Clarksville, MD.
Lim CN; Eli Lilly and Company, Indianapolis, IN.
Fu H; Eli Lilly and Company, Indianapolis, IN.
Watson DE; Eli Lilly and Company, Indianapolis, IN.
Lewin AJ; National Research Institute, Los Angeles, CA.
Landschulz WH; Eli Lilly and Company, Indianapolis, IN.
Deeg MA; Eli Lilly and Company, Indianapolis, IN.
Moller DE; Eli Lilly and Company, Indianapolis, IN.
Hardy TA; Eli Lilly and Company, Indianapolis, IN.

Diabetes Care ; 39(11): e199-e200, 2016 11.

Article em En | MEDLINE | ID: mdl-27926898

Assuntos

Diabetes Mellitus Tipo 2; Receptores de Glucagon/antagonistas & inibidores; Compostos de Bifenilo; Glucagon; Humanos

Buscar no Google

Imprimir

XML

PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Glucagon / Diabetes Mellitus Tipo 2 Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Buscar no Google

Imprimir

XML

PubMed Links